Solem CT1, Niederman MS2, Chastre J3, Wan Y1, Gao X1, Myers DE4, Haider S5, Chambers R4, Li JZ6, Van Hout BA7, Stephens JM1 1Pharmerit International, Bethesda, MD, USA, 2Winthrop-University Hospital, Mineola, NY, USA, 3Institut de Cardiologie, Paris, France, 4Pfizer, Inc., Collegeville, PA, USA, 5Pfizer, Inc., Groton, CT, USA, 6Pfizer, Inc., San Diego, CA, USA, 7University of Sheffield, Sheffield, UK
Tundia NL1, Heaton PC1, Kelton CM2, Hass S3, Fuldeore M3 1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati College of Business, Cincinnati, OH, USA, 3Abbott Laboratories, Abbott Park, IL, USA
Bushnell DM1, McCarrier KP2, Martin ML2, Paczkowski R3, Shen W3, Buesching D3 1Health Research Associates, Inc., Mountlake Terrace, WA, USA, 2Health Research Associates, Inc., Seattle, WA, USA, 3Eli Lilly and Company, Inc., Indianapolis, IN, USA
Balkrishnan R1, Kulkarni AS2, Gatwood J1, Anderson RT3, Narahari S4, Landis E4, Feldman SR4 1University of Michigan, Ann Arbor, MI, USA, 2Leo Pharma, Parsippany, NJ, USA, 3Pennsylvania State University, Hershey, PA, USA, 4Wake Forest University School of Medicine, Winston-Salem, NC, USA
Berry EA1, Kelton CM2, Yu Y2, Guo JJ3, Bian B1, Heaton PC1 1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati College of Business, Cincinnati, OH, USA, 3University of Cincinnati Medical Center, Cincinnati, OH, USA
CLINICAL OUTCOMES RESEARCH ISSUES IP6: ONCOLOGY COMPARATIVE EFFECTIVENESS RESEARCH: WHAT IS IT AND WHAT MAKES IT USEFUL? Moderator: Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA
Panelists: Sean D. Sullivan, PhD, RPh, MS, Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA; Art Small, MD, Head, Oncology Outcomes Research, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA; Jennifer Malin, MD, PhD, Medical Director Oncology, WellPoint, Inc., Thousand Oaks, CA, USA
ECONOMIC OUTCOMES RESEARCH ISSUES
IP7: DO DECISION MAKERS REALLY USE BUDGET IMPACT MODELS GENERATED BY PHARMACEUTICAL MANUFACTURERS? Moderator: Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Services, Avalere Health LLC, Washington, DC, USA Panelists: John Graham, PharmD, Group Director, Health Services, Bristol-Myers Squibb Company, Plainsboro, NJ, USA; Richard Lieblich, RPh, Vice President, Industry Relations, MedImpact Healthcare Systems, Inc, San Diego, CA, USA; John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES IP8: ACCELERATING THE DEVELOPMENT OF COMPARATIVE EFFECTIVENESS INFORMATION: DOES PHASE 3B REPRESENT AN OPPORTUNITY? Moderator: Marc L. Berger, MD, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA Panelists: Sean R. Tunis, MD, President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA; Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency, London, UK; Robert Temple, MD, Director of the Office of Medical Policy, U.S. Food and Drug Administration, Silver Spring, MD, USA
IP9: OUTSIDER PERSPECTIVES ON THE UNITED STATES COMPARATIVE EFFECTIVENESS RESEARCH MOVEMENT: REAL PROGRESS OR REAL DISAPPOINTMENT? Moderator: David Thompson, PhD, Senior Vice President, Life Sciences, OptumInsight, Medford, MA, USA Panelists: Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Federico Augustovski, MD, MSc, Director, Health Economic Evaluation and Technology Assessment Department, Hospital Italiano de Buenos Aires, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina;
Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES
IP10: STAKEHOLDER ENGAGEMENT IN PATIENT-CENTERED OUTCOMES RESEARCH (PCOR): CAN WE MAKE IT MEANINGFUL? Moderator: Patricia A. Deverka, MD, MS, Senior Research Director, Center for Medical Technology Policy, Baltimore, MD, USA Panelists: Jessie Gruman, PhD, President, Center for Advancing Health, Washington, DC, USA; Eleanor Perfetto, MS, PhD, Senior Director, Pfizer, Inc., Washington, DC, USA;
Melissa McPheeters, MPH, PhD, Research Associate Professor & Co-Director, Vanderbilt Evidence-based Practice Center, Co-Director, Emphasis Program Area on Healthcare and Public Health Research and Management, Deputy Director, Women’s Health Research, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA
WELCOME AND ISPOR SCIENTIFIC AND SERVICE AWARDS PRESENTATIONS
Mark J. Sculpher MSc, PhD 2011-2012 ISPOR President and Professor of Health Economics, Centre of Health Economics, University of York, Heslington, York, UK
2012 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARDPresented by: Michael Drummond, PhD, University of York, Heslington, York, UK, and C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA, Value in Health Co-Editors-in-Chief
2012 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARD
Presented by:Rajesh Balkrishnan, PhD, Chair, ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research Committee and Associate Professor, Department of Clinical, Social and Administrative Sciences, University of Michigan, Ann Arbor, MI, USA
AWARDEE: Susan C. Griffin, Centre for Health Economics, University of York, Heslington, York, UK
For the paper,“Dangerous Omissions: The Consequences Of Ignoring Decision Uncertainty” Health Econ 2011;20:212–24.
2012 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARD
Presented by: Anirban Basu, PhD, Chair, ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Committee and Associate Professor, Dept. of Health Services, School of Public Health, University of Washington, Seattle, WA, USA
For the paper,“Full Coverage for Preventive Medications after Myocardial Infarction” N Engl J Med 2011;365:2088-97.
2012 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD
Presented by: Shelby Reed, PhD, RPh, Chair, ISPOR Bernie J. O’Brien New Investigator Award Committee, Professor and Assistant Research Professor, Duke Clinical Research Institute, Durham, NC, USA
AWARDEE: Joanne LaFleur, PharmD, MSPH, Assistant Professor, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA
ISPOR SERVICE AND DISTINGUISHED SERVICE AWARDSPresented by: Mark J. Sculpher, MSc, PhD, 2011-2012 ISPOR President, Professor of Health Economics Centre for Health Economics, University of York, Heslington, York, UK
ISPOR STUDENT AWARDS Presented by: Zeba M. Khan, PhD, RPh, ISPOR Student Network Advisor & VP, Pricing & Market Access, Celgene Corporation, Summit, NJ, USA
PhRMA FOUNDATION 2012 AWARDS IN HEALTH OUTCOMES
Presented by: Eileen Cannon, Executive Director, PhRMA, Foundation, Washington, DC, USA
INCOMING PRESIDENTIAL ADDRESS
Deborah Marshall, PhD, MHSA 2011-2012 ISPOR President-Elect, Canada Research Chair, Health Services and Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary and Director, Health Technology Assessment, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
The US Patient Protection and Affordable Care Act (ACA), a major health care reform legislation enacted March 2010, contained 10 titles for better health and health care at lower cost for all US citizens. Some provisions of the Act were effective immediately and other provisions effective 2010 to 2020. Provisions of the Act included: a requirement for individuals not covered by health insurance to maintain a minimal essential health insurance coverage; reform in the health insurance industry - community rating so applicants with the same age/location are offered the same premium; increased insurance coverage of pre-existing conditions; expanded Medicaid eligibility; health insurance exchanges offering a marketplace for citizens and small businesses to openly compare policies and premiums; no co-pays or deductibles on an “essential benefits package”; and more.
The US health care system will be briefly presented, followed by an in-depth discussion of the titles of the Act, including what provisions of the Act have been implemented; what is going right; what is going wrong; and the financial implications of the Act. The discussion will be followed with a review of State level initiatives which aim to achieve better health and better care at lower cost. The State of Maryland which has introduced several innovative health care reform programs will be used as an example.
Moderator/Speaker: Susan Dentzer, MA, Editor-in-Chief, Health Affairs, Bethesda, MD, USA
Speakers: John E. McDonough, DrPH, MPA, Professor of the Practice of Public Health, Director of the Center for Public Health Leadership, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
Joshua M. Sharfstein, MD, Secretary, Maryland Department of Health and Mental Hygiene, Baltimore, MD, USA
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W10: DISTANT CRIES: CUSTOMISING TRIAL DESIGN AND EVIDENCE SUBMISSION IN AN EMERGING MARKETS INTENSIVE WORLD Discussion Leaders: Cyrus A. Chowdhury, MSc, Practice Leader, Global Market Access, Insight Strategy Advisors, New York, NY, USA; Corinna Sorenson, MPH, MHSA, Research Fellow, European Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK, UK; Monica Martin de Bustamante, AB, Principal, Global Market Access, Insight Strategy Advisors, Geneva, Switzerland; Rachel Beckerman, PhD, Principal, Global Market Access, Insight Strategy Advisors, Geneva, Switzerland
W12: ADAPTING TO EVOLVING GLOBAL EVIDENCE REQUIREMENTS IN MEDICAL DEVICE DEVELOPMENT PROGRAMS Discussion Leaders: Thomas Goss, PharmD, Vice President, Boston Healthcare Associates, Inc., Boston, MA, USA; Sheri Dodd, MSc, Vice President, Reimbursement, Economics and Health Policy, Cardiac Rhythm Disease Management, Medtronic Inc., Mounds View, MN, USA; Liesl Cooper, PhD, Vice President, Global Healthcare Economics, Policy & Reimbursement, Covidien, Mansfield, MA, USA; Bernd Brueggenjuergen, MD, MPH, Managing Director, Boston Healthcare GmbH, Celle, Germany
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES W13: EXPERIENCES IN THE APPLICATION OF BEST-WORST SCALING METHODS Discussion Leaders: Christine Poulos, PhD, Senior Economist, Health Preference Assessment, RTI International, Research Triangle Park, NC, USA; John F.P. Bridges, PhD, Associate Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Emily Lancsar, PhD, Associate Professor, Centre for Health Economics, Monash University, Clayton, Victoria, Australia
ASSESSING RETROSPECTIVE OBSERVATIONAL STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool" for assessing retrospective observational studies for health care decision makers will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI). The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Interpreting Retrospective Observational Studies for Health Care Decision Makers Task Force
Moderator & Speaker: Bradley Martin, PhD, RPh, PharmD, Chair, CER-CI Interpreting Retrospective Observational Studies for Health Care Decisions Task Force and Professor & Division Chair, College of Pharmacy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Speaker: William Crown, PhD, President, Innovus, Waltham, MA, USA
ASSESSING THE BODY OF EVIDENCE ACROSS MULTIPLE STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
A proposed "measurement tool" for assessing the body of evidence across multiple studies for health care decision makers as one of the work products developed by Part 2 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative (CER-CI) will be presented during this forum. The AMCP/ISPOR/NPC CER-CI was established to develop consensus-based set of principles and provide tools that would promote the development, application, and interpretation of appropriate evidence for health care technology and enhance the formulary decision-making process. Presented by the CER-CI: Synthesizing a Body of Evidence Task Force
Moderators & Speakers: Helen Sherman, PharmD, Co-Chair, CER-CI Synthesizing a Body of Evidence Task Force and Chief Pharmacy Officer of Pharmacy Services, RegenceRx, Portland, OR, USA; Brian Sweet, MBA, Co-Chair, CER-CI Synthesizing a Body of Evidence Task Force and Executive Director Development, Managed Markets, AstraZeneca Pharmaceuticals, L.P., Wilmington, DE, USA
ISPOR GOOD RESEARCH PRACTICES FOR THE ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN CHILDREN AND ADOLESCENTS
This forum will focus on best practices for PRO research with children and adolescents in the regulatory context to support claims in medical product labeling. Methodological challenges, including developmental differences, age-based cutoffs, appropriate instrument design/formatting, and approaches for establishing content validity will be discussed. Presented by the Patient-Reported Outcomes Assessment in Children and Adolescents Task Force
Moderator & Speaker: Louis Matza, PhD, Chair, ISPOR Pediatric and Adolescent PRO Task Force andResearch Scientist, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
Speakers: John J. Alexander, MD, MPH, Medical Team Leader, Division of Anti-Infective and Ophthalmology Products, US Food and Drug Administration (FDA), Silver Spring, MD, USA; Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services and Director, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA; Anne W. Riley, PhD, MS, Professor, Department of Population, Family & Reproductive Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
DESIGNING CONJOINT EXPERIMENTS: A GUIDE TO ALTERNATIVE STRATEGIES
The task force will discuss application of experimental-design approaches for discrete-choice experiments in health and health care. Topics include model identification, statistical versus response efficiency, and particular challenges in developing experimental designs for health studies. A summary and comparison of six practical experimental-design approaches will be provided. Presented by the ISPOR Conjoint Analysis Experimental Design Task Force
Moderator: John F. P. Bridges, PhD, Associate Professor, Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Speakers: Emily Lancsar, PhD, Associate Professor, Centre for Health Economics, Faculty of Business and Economics, Monash University, Melbourne, Victoria, Australia; F. Reed Johnson, PhD, Chair, ISPOR Conjoint Analysis Experimental Design Task Force, Distinguished Fellow and Principal Economist, Health Preference Assessment Group, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA; Axel Muehlbacher, PhD, Professor, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany
ISPOR VISION 2020: A LOOK TO THE FUTURE
During this forum, the ISPOR Vision 2020 Implementation Task Force Working Group Chairs will present the results of the ISPOR Vision 2020 Survey as well as Vision 2020 Implementation Task Force activities and recommended actions. Attendees will have an opportunity to respond to recommended actions. Presented by the ISPOR Vision 2020 Implementation Task Force.
Moderator: Mark J. Sculpher, MSc, PhD, ISPOR Vision 2020 Implementation Task Force Chair & Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Speakers: Ansgar Hebborn, PhD, ISPOR Vision 2020 Implementation Task Force Research Working Group Chair & Head - Global Payer & HTA Program Policy, F. Hoffmann-La Roche AG, Basel, Switzerland; Sean D. Sullivan, PhD, RPh, MS, ISPOR Vision 2020 Implementation Task Force Education Working Group Chair and Professor & Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA; Shelby Reed, PhD, RPh, ISPOR Vision 2020 Implementation Task Force Communications Working Group Chair and Associate Professor, Duke Clinical Research Institute, Durham, NC, USA
INTERNATIONAL PERSPECTIVES ON CHANGING EVIDENCE REQUIREMENTS FOR MEDICAL DEVICES AND DIAGNOSTICS: ADDRESSING THE MOVING TARGET PROBLEM FOR MEDICAL TECHNOLOGIES
Global policies and expectations related to medical device and diagnostic technologies are evolving rapidly. This forum will provide detailed insights from US, Europe, and Japan on recent policy and procedural changes in evidentiary requirements. Emerging options for aligning value demonstration with decision maker needs will be discussed. Presented by the ISPOR HTA Special Interest Group
Moderator: Annie Chicoye, PhD, Chair, ISPOR HTA of Medical Devices & Diagnostics Working Group and Executive Director for Development, Health Management Institute, ESSEC Business School Paris-Singapore, Cergy Pontoise Cedex, France
Speakers: Susan Garfield, PhD, Vice President, Bridgehead International, Wayland, MA, USA; Eric Faulkner, MPH, Director, Global Market Access, Quintiles and Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National Association of Managed Care Physicians and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA; Sophie Cros, PharmD, MBA, Director, Regulatory Affairs, Reimbursement and Health Economics, EMA, Abbott Vascular International BVBA, Diegem, Belgium; Ataru Igarashi, PhD, Assistant Professor, Department of Drug Policy and Management Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
PROBLEMS, PITFALLS, AND PRAGMATICS OF PHARMACOECONOMICS: LESSONS FROM THE AFRICAN EXPERIENCE
The use of pharmacoeconomics in health services on the African continent is limited; this, however, is not due to the lack of need but due to limited resources. The need is emphasized by the lack of access to health care on the African continent. Egypt is currently establishing a pharmacoeconomics unit within the Ministry of Health and is focusing on issues related to pricing and reimbursement process. Ghana has received training from the WHO on pharmacoeconomics and is looking into establishing a pharmacoeconomics unit within the Ministry of Health. Nigeria is taking steps to start promoting pharmacoeconomics in the country. South Africa has pharmacoeconomic guidelines within the government sector while HTA is an accreditation requirement in the private sector. This forum will provide an in-depth review of African attitudes toward pharmacoeconomics, knowledge of drug costs, awareness and perceived uses of pharmacoeconomic literature, views on perceived barriers to pharmacoeconomic implementation and how those needs and barriers should be addressed. Speakers will provide knowledge and understanding of current principles and practices on pharmacoeconomics, relevant to the African countries. Presented by the ISPOR Egypt, Ghana, Nigeria and South Africa Regional Chapters
Moderator: Emmanuel Ankrah Odame, MBChB, MPH, Health Policy Analyst, Ghana College of Physicians and Surgeons, Accra, Ghana
Speakers:Mohammed Hassan Solayman, MSc, Assistant Lecturer, Faculty of Pharmacy, Clinical Pharmacy Department, Ain Shams University, Cairo, Egypt; Martha Gyansa-Lutterodt,MA, MSc, Director of Pharmaceutical Services and Chief Pharmacist, Ghana Ministry of Health, Accra, Ghana; Anthony Waka Udezi, MPharm, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Benin, Benin City, Nigeria; Jacques Snyman, MBChB, MPharmMed, MD, President, ISPOR South Africa Regional Chapter and Director, Product Development, Agility Global Health Solutions, Pretoria, South Africa
Dr. Ramsey is general internist and health economist. He is a Member in the Cancer Prevention Program, Division of Public Health Science at the Fred Hutchinson Cancer Research Center. He directs the Cancer Technology Assessment Group, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the School of Medicine, School of Pharmacy, and the Institute for Public Health Genetics at the University of Washington. He also directs the Cancer Prevention and Survivorship Program at the Seattle Cancer Care Alliance.
Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs, and cost-effectiveness of treatments for lung, colorectal, and prostate cancer. His current studies—funded by the National Cancer Institute, National Human Genome Research Institute, Centers for Disease Control and Prevention, and several pharmaceutical manufacturers—include projects to develop a genetic screening policy model for colorectal cancer, a multicenter study of decision making for men with newly diagnosed prostate cancer, and studies of cancer screening, incidence, treatment, and outcomes for Native Americans diagnosed with cancer. Along with investigators at the University of Washington, Dr. Ramsey co-directs an NCI-funded training program in Biobehavioral and Cancer Outcomes Research. He is a member of the Institute of Medicine’s National Cancer Policy Forum.
Dr. Ramsey has served ISPOR in several capacities: as Chair, Task Force on Cost-Effectiveness Analysis alongside Clinical Trials; Director, 2005-2007 ISPOR Board of Directors; Chair, 12th Annual International Meeting, and Chair and current member, Value in Health Management Advisory Board.
Nicola J. Cooper, PhD
Nicola J. Cooper, PhD, is a Professor of Healthcare Evaluation Research at the University of Leicester, UK. Her research experience spans a range of academic disciplines including health economics, health services research and medical statistics, and most excitingly, the interface and integration of all three. Nicola joined the Biostatistics group at Leicester in 2000 and since then, her research has focused on the development and application of methods for evidence synthesis and economic decision modelling to inform health technology appraisals. This research has led to collaborations with renowned experts in the area both nationally and internationally, leading to numerous research grants and the development of specialist courses delivered worldwide. The paper, on which the 2012 ISPOR Award for Value in Health Paper of the Year was awarded, was funded by an MRC methodology grant and is an example of the collaborative research Nicola is currently undertaking.
Susan C. Griffin, PhD
Susan C. Griffin, PhD, is a Senior Research Fellow based in the Team for Economic Evaluation and Health Technology Assessment. She joined the Centre for Health Economics in 2002 and holds a BSc in Economics, an MSc in Health Economics and a PhD on ‘Dealing with uncertainty in the economic evaluation of health care technologies.’ In 2008, Dr. Griffin became a Research Council UK Academic Fellow in Health Economics and Public Health. She also helped to develop a short course on the use of regression analysis for health economic evaluation. Dr. Griffin currently serves as a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee. Dr. Griffin has contributed to numerous technology appraisals for NICE in her role as a member of one of the independent academic groups contracted to conduct assessments and evidence reviews for NICE. In addition, Dr. Griffin has worked on economic evaluations in the fields of cardiovascular disease, HIV/AIDS, cancer and mental health. Her research interests include the use of decision-analytic models in cost-effectiveness analysis and the use of evidence synthesis techniques and value of information analysis. Dr. Griffin is currently researching the application of methods for economic evaluation in the field of public health.
Niteesh K. Choudhry, MD, PhD
Niteesh K. Choudhry, MD, PhD, is an internist and health services researcher whose work focuses on the clinical and economic consequences of evidence-based therapies for the management of common chronic conditions. He is particularly interested in the design and evaluation of novel strategies to overcome barriers to treatment initiation and long-term medication adherence. His work employs a broad range of methods including randomized policy evaluations, cost-effectiveness modeling, claims analyses, and surveys. Dr. Choudhry is an Associate Professor at Harvard Medical School and Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. He received his MD and completed his residency training in Internal Medicine at the University of Toronto, did his PhD in Health Policy at Harvard University and was a Fellow in Pharmaceutical Policy Research at Harvard Medical School. He practices inpatient general internal/hospital medicine and is actively involved in resident education.
Joanne LaFleur, PharmD, MSPH
Joanne LaFleur, PharmD, MSPH, is Assistant Professor in the Department of Pharmacotherapy within the University of Utah College of pharmacy. She has a joint appointment as a researcher in the Salt Lake City Veterans Affairs Informatics, Decision Enhancement, and Surveillance (IDEAS) center, where she focuses on applying the tools of health economics, biomedical informatics, and pharmacoepidemiology to outcomes research. She received her PharmD degree from the University of Utah in 2003 and went on to complete a Fellowship in Pharmacoeconomics and Outcomes Research and a Master’s degree in Public Health in 2005, both at the University of Utah. She spent 4 years as faculty on the research track, and recently changed tracks to join the tenure track faculty. The focus of her CDA, entitled “Knowledge engineering for decision support in osteoporosis,” is on the development of clinical decision support tools for osteoporotic fracture prevention.